Stockreport

ImmunityBio: A Small Bet Is Warranted [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF Anktiva, IBRX's lead therapy, is ramping up sales post-J-code but faces competition from JNJ's TAR-200 and regulatory setbacks. Promising early data from the t-haNK p [Read more]